Last reviewed · How we verify

Urispas (FLAVOXATE)

FDA-approved approved Small molecule Quality 50/100

Urispas (Flavoxate) is a cholinergic muscarinic antagonist, a small molecule drug that targets the potassium voltage-gated channel subfamily H member 2. It was originally developed and is currently owned by a pharmaceutical company. Urispas is used to treat various urinary tract symptoms such as dysuria, increased urinary frequency, and nocturia. The drug is off-patent and has multiple generic manufacturers. As a cholinergic muscarinic antagonist, Urispas works by blocking the action of acetylcholine at muscarinic receptors in the bladder, reducing muscle spasms and improving urinary flow.

At a glance

Generic nameFLAVOXATE
Drug classCholinergic Muscarinic Antagonist
TargetPotassium voltage-gated channel subfamily H member 2
ModalitySmall molecule
Therapeutic areaPain
PhaseFDA-approved
First approval1970

Approved indications

Common side effects

Drug interactions

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: